



# WEBINAR Call for Eol for the IMI pool of patient experts

Elli Karagianni Scientific project officer 18.06.2019

### Outline of the webinar

- Part one
  - About the Innovative Medicines Initiative
     Mission, Governance, topics development, Call process, projects.
  - IMI and patient engagement.
- Part Two
  - The IMI Pool of patient experts.
  - The Call for Eol and how to apply
- Part Three
  - Q&A







## Part One What is IMI and how does it work?

### IMI - Europe's partnership for health

#### **IMI** mission

IMI facilitates open collaboration in research to advance the development of, and accelerate patient access to, personalised medicines for the health and wellbeing of all, especially in areas of unmet medical need.



## How is IMI addressing the challenges in drug development?

Through IMI's projects we are trying to...

- Put patients at the centre
- Share risk (among public & private players)
- Increase efficiency (by developing common tools)
- Reduce duplication of effort (esp. at early stages)
- Reduce timelines (by using a personalised medicine approach)
- Integrate the latest science into drug development
- Use data and knowledge management to work more effectively

We do this by creating a **neutral platform** where **all involved** in drug development – academics, industry, SMEs, patients, regulators, others – can engage in **open collaboration** on **shared challenges**.









public contribution €1.638 bn

funding from Horizon 2020 € 3.276 bn

EU funding goes to

SMES IIIII

UNIVERSITIES ||||||

PATIENTS, REGULATORS...

IN-KIND PRIVATE CONTRIBUTION €1.425 bn

EFPIA companies receive no funding



(Associated Partners, e.g. charities, non-EFPIA companies)

EFPIA contribute researchers, laboratories, generation of data, curation of compounds, and cash


#### Public and private partners collaborate in IMI2 projects

Accelerating research and development


Speeding up patient access to innovative treatments


Improving patient outcomes and safety of medicines

### **IMI** Governance




### IMI in a nutshell






### **IMI's standard Call process**





### What does an IMI project look like?






53 organisations from 11 countries, working accross 7 hematological malignancies



### Collaborations in an IMI project





### Added value of IMI

- Bringing together groups that would normally not work together, including competitors
  - Attracting new partners leading to a more diverse community
  - Creating new networks, maintained after projects end
- Addressing the most challenging diseases and cross-cutting issues
- Maximising the pooling of resources and amplifying scientific and financial investments
- Relevant outcomes for industry, direct benefits to patients, impacts on regulatory processes
  - Including elements of or dedicated to education and training activities
  - Increasing co-authored & cross-sectors publications with high citation impact








## IMI and patients: a dynamic partnership for health

## Paving the way: IMI's first steps to engage with patients

- Regular involvement of patients and patient representatives as speakers and panellists in IMI events.
- Surveys by the London School of Economics (LSE) on patient involvement in IMI projects and patients' opinion of IMI (2013).
- Events dedicated to patient outreach and involvement (2013 patient-focus meeting, 2014 Diabetes patient event).
- Patient engagement strategy workshop (2016).
- Patient-event co-organised with the European Patient Forum (EPF) with the IMI Stakeholder Forum (2017).
- Outreach to patients in IMI Calls for proposals.



## Patient involvement in IMI projects



About 20.5 % of active projects have patients' organisations represented in the consortium as full partners.

About 30 %
of active projects
have patient
organisations
represented in
advisory boards or
have consulted
with patient

About 50 %
of IMI projects give
a strong voice to
patients, either by
having them as full
partners or giving
them an active role
in the project.



## PARADIGM – for better patient engagement in medicines development

#### Mission

provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement and demonstrates the 'return on engagement' for all players



#### **Objectives**

- develop processes and tools for three key decision-making points:
   research priority setting, design of clinical trials and early dialogue.
- integrate the needs, perspectives and expectations of all actors (including vulnerable populations) involved and produce metrics to measure the impact of patient engagement.

### EUPATI graduates - making a difference



- 150 graduates
- 58 disease areas, 31 countries
- 14 National Platforms in Europe
- More & deeper involvement in R&D thanks to EUPATI
- ✓ Sustainability (course, toolbox maintained by EPF)

## Moving forward-from initial engagement to strategic/meaningful engagement

- IMI has a patient representative on its Scientific Committee
- Creation of the IMI pool of patient experts How?
  - Launch an open Call for Expression of Interest.







## Part two: Call for Eol for the IMI pool of patient experts

### Purpose of the Call

Identify patients/patient informal carers interested in participating in IMI activities both at strategic and operational levels



Drawing from this Patient Expert Pool, the IMI Programme Office will invite patients with the most suitable profile, to perform a variety of roles and tasks depending on the need and topics discussed



Their input will contribute in shaping the IMI portfolio and improve quality of IMI projects from patient perspective through early and meaningful engagement



### The role of patient experts

Patients and patient carers can bring a unique perspective based on their real-life experience with a disease.

Patient experts will be invited to provide input to the IMI Programme Office and to the IMI Advisory Bodies through:

- Input on the IMI scientific strategy;
- Participation in early consultations to identify research areas for future Call topics;
- Participation in reviewing proposals submitted within an IMI Call, or reviewing IMI projects;
- Participation in panels to review IMI patient-related communications content;
- Participation in IMI events, e.g. Stakeholder Forum.



### What's in it for patients?

- Influence research, and identify gaps from the perspective of patients and carers
- Receive funding
- Form networks with leading researchers
- Access to the latest science
- Take part in IMI work to help improve health and wellbeing in Europe
- Provide patient perspective to help shape IMI's portfolio and improve quality of IMI projects
- Contribute to enhancing transparency and trust between IMI and patients



## Who can be a member of the IMI pool of patient experts?

#### **Eligibility criteria**

- ✓ Be a patient or a patient informal carer
- ✓ Be resident of one the following groups of countries :
  - a) Member States of the European Union,
- b) Countries associated with the EU's research framework programmes.
- c) Residents from the broader European Region as defined by WHO
  - ✓ Possess working knowledge of English

Applications are submitted online. Deadline for submissions **16 July 2019** at **17:00** CEST Brussels Time

We strongly recommend that you read the Call document carefully before applying.

## Organise targeted/meaningful interactions

Invitations/assignments will be assessed in advance by the IMI Programme Office and will be based upon patient expert profile. Patient expert profile =(A+B+C)

#### A)Disease/condition area of interest based on IMI Strategic research agenda (S.R.A)

- Neuro-psychiatric disorders and brain diseases including pain
- Inflammatory and Immune-mediated diseases
- Cancer
- Metabolic diseases including cardiovascular diseases
- Rare/orphan diseases
- Neurodegenerative diseases
- Infectious diseases.

#### B) Skills related to IMI activities

- Knowledge and/or experience of research and innovation activities.
- Knowledge and/or experience of the pharmaceutical sector/medicines development cycle.
- Knowledge and /or experience of IMI and public-private partnerships.
- Experience of working/interacting with different stakeholders in medicines development such as HTAs,
   regulatory authorities, payers, medical practitioners, etc.

#### C) Motivation for applying



A specific disease/condition of an area. e.g. type 1 diabetes

### IMI

A C T I V I T I

### Rules of engagement.

- Tasks/activities assigned to patient experts may be carried out at the IMI2 JU premises in Brussels, at any other premises where an IMI2 JU event is taking place, or remotely, using electronic communication tools.
- Experts will be required to abide by the rules of procedure of any IMI2 JU bodies / groups they participate in.
- Experts will act in their personal capacity. They must respect the confidential character of the proceedings in which they participate and protect any information whose disclosure could damage the interests of IMI2 JU.
- All experts who are part of the pool will be requested to sign a declaration of interests form. Experts assigned to certain tasks may be required to sign a declaration of non-conflict of interest for that specific task.



### Reimbursement / Allowances

- Invited experts will be entitled to reimbursement and allowances only for the activities they are requested to perform. The reimbursement and allowances will depend on the nature of the task each expert is requested to perform.
- Allowances may be increased for experts with disabilities

### **Transparency**

Experts invited to perform tasks and roles associated with the evaluation of project proposals and/or the monitoring of projects will be requested to register in the European Commission Register of experts. Additionally, the names of experts who have been assigned to such tasks will be published on the general H2020 'Funding and Tenders Portal'.



### **Privacy Policy and Data Protection**

All personal data will be dealt with in compliance with the Regulation (EU) 2018/1725 of the European Parliament and of the Council of 23 October 2018 on the protection of natural persons with regard to the processing of personal data by the Union institutions, bodies, offices and agencies and on the free movement of such data.

For more information please visit:

https://www.imi.europa.eu/legal-notice-privacy







How to apply: step by step guide
Please go to:
<a href="https://www.imi.europa.eu/get-involved/patients/imi-pool-patient-experts">https://www.imi.europa.eu/get-involved/patients/imi-pool-patient-experts</a>





# For any further information please contact the IMI2 JU Programme Office:

Patients@imi.europa.eu





### Part three: Q&A





## Thank you